[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE510551T1 - Hemmung von gs-fdh zur modulierung der no- bioaktivität - Google Patents

Hemmung von gs-fdh zur modulierung der no- bioaktivität

Info

Publication number
ATE510551T1
ATE510551T1 AT01987141T AT01987141T ATE510551T1 AT E510551 T1 ATE510551 T1 AT E510551T1 AT 01987141 T AT01987141 T AT 01987141T AT 01987141 T AT01987141 T AT 01987141T AT E510551 T1 ATE510551 T1 AT E510551T1
Authority
AT
Austria
Prior art keywords
bioactivity
inhibition
fdh
modulate
glutathione
Prior art date
Application number
AT01987141T
Other languages
English (en)
Inventor
Jonathan Stamler
Limin Liu
Alfred Hausladen
Raphael Nudelman
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE510551T1 publication Critical patent/ATE510551T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT01987141T 2001-01-11 2001-12-14 Hemmung von gs-fdh zur modulierung der no- bioaktivität ATE510551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/757,610 US7179791B2 (en) 2001-01-11 2001-01-11 Inhibiting GS-FDH to modulate NO bioactivity
PCT/US2001/044709 WO2002055018A2 (en) 2001-01-11 2001-12-14 Inhibiting gs-fdh to modulate no bioactivity

Publications (1)

Publication Number Publication Date
ATE510551T1 true ATE510551T1 (de) 2011-06-15

Family

ID=25048508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987141T ATE510551T1 (de) 2001-01-11 2001-12-14 Hemmung von gs-fdh zur modulierung der no- bioaktivität

Country Status (5)

Country Link
US (5) US7179791B2 (de)
EP (1) EP1349562B1 (de)
AT (1) ATE510551T1 (de)
AU (1) AU2002239387A1 (de)
WO (1) WO2002055018A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
WO2005000229A2 (en) * 2003-06-04 2005-01-06 Duke University Compositions and methods for modulating s-nitrosoglutathione reductase
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US8980930B2 (en) 2004-06-25 2015-03-17 The Johns Hopkins University Angiogenesis inhibitors
CA2577169A1 (en) 2004-08-16 2006-02-23 The University Of Queensland Metabolism-modulating agents and uses therefor
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20080025972A1 (en) * 2006-07-26 2008-01-31 Duke University Treating sex steriod responsive disorders
WO2008026018A1 (en) * 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
JP2011507811A (ja) * 2007-12-13 2011-03-10 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 哺乳動物のｓ−ニトロソグルタチオンレダクターゼを阻害するための材料および方法
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
US8642628B2 (en) * 2008-08-15 2014-02-04 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase
DK2315591T3 (en) 2008-08-15 2016-06-06 Nivalis Therapeutics Inc NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents
WO2011038204A1 (en) 2009-09-25 2011-03-31 N30 Pharmaceuticals, Llc Novel dihydropyrimidin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors
JP5748154B2 (ja) 2009-12-16 2015-07-15 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼの新規なチオフェン系阻害薬
JP5639665B2 (ja) 2010-02-12 2014-12-10 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのクロモン阻害剤
SI2533638T1 (sl) 2010-02-12 2016-05-31 Nivalis Therapeutics, Inc. Novi inhibitorji S-nitrozoglutation reduktaze
DK2592934T3 (en) 2010-07-16 2015-10-26 Nivalis Therapeutics Inc NOVEL dihydropyridin-2 (1H) -one compounds as S-NITROSOGLUTATHIONREDUKTASEINHIBITORER and neurokinin-3 receptor antagonists
WO2012039718A1 (en) 2010-09-24 2012-03-29 N30 Pharmaceuticals, Llc Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists
EP2977050A1 (de) 2010-10-08 2016-01-27 Nivalis Therapeutics, Inc. Neuartige substituierte chinolinverbindungen als s-nitrosoglutathion-reduktasehemmer
JP5990187B2 (ja) 2010-12-16 2016-09-07 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
WO2013006635A1 (en) * 2011-07-05 2013-01-10 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents for liver toxicity
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP3174891B1 (de) 2014-07-24 2020-01-29 W.R. Grace & CO. - CONN. Kristalline form von nicotinamidribosid
WO2016130691A1 (en) * 2015-02-10 2016-08-18 Duke University Method of treating heart failure
CN104622886A (zh) * 2015-03-05 2015-05-20 中国人民解放军第二军医大学 烟酰胺核糖在制备治疗非酒精性脂肪性肝炎的药物中的应用
US10189872B2 (en) 2015-03-09 2019-01-29 W. R. Grace & Co.-Conn Crystalline form of nicotinamide riboside
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
CN110662542A (zh) 2016-11-11 2020-01-07 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
KR102464435B1 (ko) * 2020-09-22 2022-11-07 의료법인 성광의료재단 D-글루타티온을 포함하는 염증 질환의 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US4507287A (en) * 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5238683A (en) * 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ATE144142T1 (de) * 1991-01-10 1996-11-15 Transcend Therapeutics Inc Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
AU5620598A (en) 1996-12-31 1998-07-31 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
NZ508249A (en) * 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
AR022116A1 (es) * 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
MXPA02000112A (es) * 1999-06-28 2002-07-02 Janssen Pharmaceutica Nv Inhibidores de la replicacion del virus sincitial respiratorio.
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity

Also Published As

Publication number Publication date
EP1349562B1 (de) 2011-05-25
AU2002239387A1 (en) 2002-07-24
EP1349562A4 (de) 2008-08-06
US20100015121A1 (en) 2010-01-21
US7179791B2 (en) 2007-02-20
US8217006B2 (en) 2012-07-10
US20140235528A1 (en) 2014-08-21
US20120245116A1 (en) 2012-09-27
US7615535B2 (en) 2009-11-10
WO2002055018A2 (en) 2002-07-18
US20070111949A1 (en) 2007-05-17
US20020128205A1 (en) 2002-09-12
EP1349562A2 (de) 2003-10-08
WO2002055018A3 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
MY138732A (en) Conjugated complement cascade inhibitors
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE60212613D1 (de) Doxycyclin zur behandlung von akne
DE60139466D1 (de) Behandlung von diabetes
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
DE60013486D1 (de) Verbindungen
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
SE0004101D0 (sv) New use
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE228840T1 (de) Neue verwendung von ropivacain zur schmerzbehandlung
WO2003103612A3 (en) METHODS OF USING PROSTACYCLINE TO TREAT RESPIRATORY SYNCYTIAL VIRAL INFECTIONS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties